Pfizer Inc. (PFE.SN)
| Previous close | 28.90 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 28.90 - 28.90 |
| 52-week range | 25.63 - 38.72 |
| Volume | |
| Avg. volume | 83 |
| Market cap | 167.108B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.05 |
| Earnings date | 30 July 2024 - 05 Aug 2024 |
| Forward dividend & yield | 1.68 (5.81%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | N/A |
- Yahoo Finance Video
FDA considers updating COVID boosters, Novavax stock reacts
The US Food and Drug Administration (FDA) is set to vote on recommendations for updated COVID-19 booster shots as the KP.2 variant strain begins to spread across the US. Yahoo Finance Health Reporter Anjalee Khemlani joins Market Domination to discuss the impact this is having on vaccine makers, particularly Novavax (NVAX), whose stock has shot up in Monday's session. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
Business WirePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK, June 03, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 11:20 a.m. Eastern Daylight Time.
Business WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK, June 01, 2024--Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting (LBA7000) and at the 29th European Hematology Association (EHA) Annual Meeting (S225). Th
